Ƶ

Lyumjev OK'd for Kids; Sand for Weight Loss? AGA's New Obesity Guidelines

— News and commentary from the endocrinology world

Ƶ MedicalToday
Endo Break over a computer rendering of a man with illustrated body organs.

The FDA expanded the indication for rapid-acting mealtime to now also include children ages 1 year and older with diabetes, based on the phase III , Eli Lilly announced.

Estimating glomerular filtration rate based on cystatin C level helped to more accurately stratify patients with at risk for cardiovascular disease compared with serum creatinine level. (JAMA Network Open)

In a real-world analysis of patients with thyroid eye disease treated with a full course of , only 4.9% were prescribed a second course within 2 years, maker Horizon Therapeutics said.

Catch up on what the is doing to fight back against endocrine-disrupting chemicals in the U.S. water supply. (JAMA)

Patients with stemming from severe obesity saw changes in microRNA expression, which wasn't reversed with bariatric surgery, but was helped with continuous positive airway pressure (CPAP). (International Journal of Obesity)

Could sand be the next treatment frontier in ? (ScienceDaily)

The American Gastroenterological Association (AGA) released on the use of pharmacotherapies, such as semaglutide (Wegovy) and liraglutide (Saxenda), for weight loss in people with overweight and obesity. They also identified the use of Gelesis100 oral superabsorbent hydrogel as a "knowledge gap." (Gastroenterology)

Merck KGaA in France is facing legal ramifications for allegedly misleading patients after it changed the formulation of . (FiercePharma)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.